Kazia Therapeutics
KZIA
Kazia Therapeutics (KZIA) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Canaccord Genuity | Initiated Coverage | Buy | $29.00 | Aug 13, 2026 |
| BTIG | Maintained | Buy | $34.00 | Jul 15, 2026 |
| BTIG | Initiated Coverage | Buy | $34.00 | Jul 1, 2026 |
| Lake Street | Initiated Coverage | Buy | $32.00 | Jun 11, 2026 |
| Laidlaw & Co. | Initiated Coverage | Buy | $25.00 | Apr 15, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 | Jan 28, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 from $13.00 | Dec 12, 2025 |
| Maxim Group | Maintained | Buy | $20.00 from $15.00 | Oct 2, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 from $2.00 | Jul 10, 2025 |
| Maxim Group | Maintained | Buy | $15.00 | Jun 11, 2025 |
| Maxim Group | Initiated Coverage | Buy | $3.00 | Feb 6, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $2.00 | Jul 12, 2024 |
| HC Wainwright & Co. | Upgraded | Neutral → Buy | $2.00 | Apr 11, 2023 |
Frequently asked questions
What is the latest analyst rating on KZIA?
On Aug 13, 2026, Canaccord Genuity initiated coverage of Kazia Therapeutics at Buy with a price target of $29.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.